Navigation Links
genae Appoints Chief Medical Officer
Date:4/16/2012

ANTWERP, Belgium, April 16, 2012 /PRNewswire/ --

genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services.

"I am delighted to welcome Catalina, whose extensive clinical and research expertise will be of great benefit to the many aspects of our services offering," said Bart Segers, Chairman and CEO of genae. "We believe that her experience as an interventional cardiologist provides her with a unique opportunity to view our services with an unsurpassed balance of clinical insight, business acumen and regulatory and safety compliance.

Dr. Trana holds the position of Cardiology Specialist at the Interventional Cardiology Department of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She was a fellow at the Cardiovascular Center Aalst, OLVZ, Aalst, Belgium and worked and trained at the Interventional Cardiology Department and Cardiovascular Surgical Department of the Cardiovascular Center in Iasi, Romania; and at the Catholic University of Leuven, Belgium. Her scientific and research work is illustrated by peer-reviewed publications and presentations during international congresses and symposia.

About genae

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for Clinical Trial Management, Core Laboratory Services and Additional Services for the Medical Industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium.

genae Americas Inc. is a privately held company with principal offices in Cleveland, OH.

Please visit: http://www.genae.com

Company Contact

genae associates nv
Justitiestraat 6B
2018 Antwerp, Belgium
Aly Talen, RN
Sr. VP Business Development
+32-3-290-03-06
aly.talen@genae.com

genae Americas Inc.
Global Cardiovascular Innovation Center
10000 Cedar Avenue
Cleveland, OH 44106, USA
Dimitri Buytaert, PT CCRA
President
+1-216-445-4535
dimitri.buytaert@genae.com


'/>"/>
SOURCE genae associates nv
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
2. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
3. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
6. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Special purpose needles are used in target specific ... cells from organs or lumps and are available in the ... market for special purpose needles is showing a steady growth ... the global special purpose needles market is projected to expand ... and is expected to be valued at US$ 17,261.5 million ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Institute for the Commercialization of Public Research ... finalized a funding agreement SegAna, LLC, an ... at University of Central Florida. The Florida Institute ... and bridges early funding gaps for companies spinning ...
Breaking Medicine Technology:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... of its latest transitional care facility – Avamere Transitional Care of Puget ... square foot short-term, post-acute health care center will provide patients recovering from illness ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... 70th Annual Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing ... , One in 26 people will be diagnosed with epilepsy within their lifetime. ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... Keynote speaker for the 21st Annual International Congress on Hematologic Malignancies®: Focus on ... PER® president, Phil Talamo said, “We are honored to have Amy E. Herman ...
Breaking Medicine News(10 mins):